Sugi Predict

Sugi Predict / Compounds / SCHEMBL178498

SCHEMBL178498

SCHEMBL178498

CNC(C)c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ POLB P06746 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8284221 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
SCHEMBL10087237 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
Hydrochloric Acid SCHEMBL26650359 0.98 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
Hydrochloric Acid SCHEMBL26650364 0.98 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
Hydrochloric Acid SCHEMBL29532516 0.98 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
SCHEMBL30606202 0.84 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
SCHEMBL28277824 0.80 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
SCHEMBL2669165 0.79 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL10087160 0.78 POLB (0.47) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA
SCHEMBL508662 0.78 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2POLBCYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116916924-B MALT1 modulators and uses thereof 稀有生物科学股份有限公司 2026-02-27 — — CN disclosed
US-20230391781-A1 MALT1 MODULATORS AND USES THEREOF RHEOS MEDICINES, INC. (US) 2023-12-07 — — US disclosed
CN-116916924-A MALT1 modulators and uses thereof 稀有生物科学股份有限公司 2023-10-20 — — CN disclosed
EP-4228647-A1 MALT1 MODULATORS AND USES THEREOF Rheos Medicines, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081995-A1 MALT1 MODULATORS AND USES THEREOF RHEOS MEDICINES, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081967-A1 MALT1 MODULATORS AND USES THEREOF RHEOS MEDICINES, INC. (US) 2022-04-21 — — WO disclosed
WO-2021018298-A1 INDOLO-SEVEN-MEMBERED ACYLOXIME COMPOUNDS AS PARP INHIBITORS 南京明德新药研发有限公司 2021-02-04 — — WO disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20160002221-A1 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LTD (CN) 2016-01-07 — — US disclosed
EP-2121617-B1 CB1 RECEPTOR MODULATORS 7TM PHARMA AS (DK) 2014-01-22 — — EP disclosed
EP-2431362-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-03-21 — — EP disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 — — US disclosed
US-8124634-B2 CB1 receptor modulators 7TM PHARMA A/S (DK) 2012-02-28 — — US disclosed
WO-2010131669-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 大日本住友製薬株式会社 (JP) 2010-11-18 — — WO disclosed
US-20100010061-A1 CB1 RECEPTOR MODULATORS 7TM PHARMA A/S (DK) 2010-01-14 — — US disclosed
US-20090325962-A1 TYROSINE DERIVATIVE GENENTECH, INC. (US) 2009-12-31 — — US disclosed
US-7595399-B2 Tyrosine derivatives GENENTECH, INC. (US) 2009-09-29 — — US disclosed
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED (GB) 2007-05-17 — — US disclosed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325962-A1 TYROSINE DERIVATIVE VCAM1, ICAM1, ITGB4 ALDH1A1 401/4885SMN1; SMN2 4604/4885POLB 4652/4885
US-20230391781-A1 MALT1 MODULATORS AND USES THEREOF MALT1, SQSTM1, PPP1R10 ALDH1A1 3447/4885SMN1; SMN2 2034/4885POLB 4698/4885
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors PDE4B, PDE3B, PDE4A ALDH1A1 1120/4885SMN1; SMN2 3929/4885POLB 1575/4885
US-20160002221-A1 Substituted Pyridopyrazines as Syk Inhibitors SYK, BTK, LYN ALDH1A1 3626/4885SMN1; SMN2 3889/4885POLB 2234/4885
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors SYK, BTK, LYN ALDH1A1 3626/4885SMN1; SMN2 3889/4885POLB 2234/4885
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 ALDH1A1 96/4885SMN1; SMN2 2373/4885POLB 4739/4885
US-20100010061-A1 CB1 RECEPTOR MODULATORS CNR1, CNR2, GPR6 ALDH1A1 3325/4885SMN1; SMN2 3896/4885POLB 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.